Clinical Trial Update: Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of enfortumab vedotin and pembrolizumab with a selective bladder-sparing approach for muscle-invasive bladde…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• Enfortumab Vedotin (Padcev) (enfortumab vedotin)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Matthew Galsky | Conditions: Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Status: RECRUITING